-
The FDA has approved injectable poly-L-lactic acid, an injectable filler to correct facial fat loss in HIV patients.
-
The key to a four-session HIV prevention for positives program targeting Latinos, called Positively Latino, is the adaptation of the theoretical model of motivational interviewing, which is a different approach than the traditional case management model.
-
Until recently, an HIV and hepatitis C (HCV) coinfected patient who was managing well with HIV antiretrovirals might die from liver disease due to HCV infection. Now treatment has advanced, and the health prospects for coinfected patients are brighter than ever.
-
-
Put syphilis testing on your radar screen: Updated guidelines from the U.S. Preventive Services Task Force (USPSTF) recommend that health care providers perform syphilis screening on pregnant women and people who are at high risk for syphilis infection.
-
Which drugs might impact the efficacy of the birth control pill? Comments are offered by Andrew Kaunitz, MD, professor and assistant chair in the obstetrics and gynecology department at the University of Florida Health Science Center/Jacksonville, and Susan Wysocki, RNC, NP, president and chief executive officer of the National Association of Nurse Practitioners in Womens Health.
-
If women could directly access hormonal contraception in pharmacies without a prescription, would they be interested in doing so, provided that pharmacists screen for the methods? A new survey indicates they would.
-
Your next patient is a 17-year-old who admits she has a hard time remembering to take the Pill, but says she wants to avoid unintended pregnancy. When you begin to counsel on the injectable contraceptive Depo Provera [depot medroxyprogesterone acetate (DMPA), Pfizer, New York City], what do you tell her about the drug?
-
Mark your calendars for the Contraceptive Technology Quest for Excellence conference, set for Nov. 11-12 in Atlanta.
-
Clinicians who opt to use azithromycin for treatment of early syphilis should review recently published research that indicates that at least 10% of syphilis samples from patients at sexually transmitted disease (STD) clinics in four cities had a strain resistant to the antibiotic.
